G'day PJ,
As far as I can see, it would appear that camptosar is cpt-11, is this what
you found? See the following info.
Love Mam
98639652 (Reference 1 of 4) Flag for Printing Order a Photocopy
Camptosar's active species, SN-38 is an MDR-1 substrate (Meeting abstract).
von Palffy S, Mechetner E, Garcia R, Fruehauf JP
Proc Annu Meet Am Assoc Cancer Res (1997) 38:A2652 1997 ISSN:
0197-016X
P-Glycoprotein
Camptothecin
Drug Resistance, Neoplasm
Substrate Specificity
Tumor Cells, Cultured
Cancerlit Database
MEETING ABSTRACT
Drug Synergism
Cyclosporine
Human
Abstract
Camptosar has been approved for 2nd line therapy of colon cancer. Greater
than 50% of colon cancer specimens have been found to overexpress MDR-1.
MDR-1 may be a significant factor in colon cancer drug resistance. We
therefore evaluated the impact of MDR-I expression on camptosar resistance.
The MDR-1 positive MCF-7 40F cells were 12-fold more resistant to SN-38 than
Top of Abstract
their MDR-1 negative parent MCF-7 WT cell line. MCF-7 40F
resistance to SN-38 was fully reversed by 3 ug/mL of cyclosporin A. The
substrate specificity of Pgp for SN-38 was evaluated using the UIC2 Shift
Assay, which demonstrated increased UIC2 antibody binding in the presence of
SN- 38. These data demonstrate that SN-38 resistance can be mediated by the
MDR-1 P-glycoprotein.
Oncotech Inc.
Irvine
CA 92614
and:
The Food and Drug Administration requires a detailed understanding of the
interactions of new agents with blood proteins prior to approval for use.
These regulatory requirements are based upon the knowledge that it is the
free drug fraction of an agent which has the potential to elicit biological
activity. In order to directly monitor drug- protein interactions in
plasma, a fluorescence spectroscopic method employing two-photon excitation
(TPE) was implemented. Direct fluorescence
Top of Abstract
detection of SN-38 was achieved in plasma at sub- micromolar
levels using two-photon excitation (2PE) at 790 nm. Both SN-38 as well as
Camptosar were found to be amenable to study using two photon methodologies.
Anisotropy measurements are currently being evaluated as a means of directly
determining the free and bound drug levels of SN-38 in human plasma. TPE
fluorescence methods may eventually allow for direct and rapid screening of
protein binding parameters in individual patient samples
-----Original Message-----
From: PSerritell@aol.com <PSerritell@aol.com>
To: mol-cancer@lists.meds.com <mol-cancer@lists.meds.com>
Date: Friday, 6 November 1998 8:22
Subject: [MOL] PJ NEEDS INFORMATION
>Hi Gang:
>Mom just called regarding her visit today with oncologist.
>
>1-The onc said no 5FU Chemo until the shingles are gone.
>2-The onc said that since moms CEA went up to 15 that they will start her
on
>Campostar.
>3-Mom gained 4 more pounds since being out of hospital. (8 total since
>hospital)
>
>
>Now my questions are
>1-Has any had the shingles and still received their chemo
>2-What is Campostar Chemo (website or info appreciated)
>3-Can Mom go back to using 5FU after Campostar?
>4-Is weight gain good?
>
>I though I knew a site where Campostar is but I can't seem to find it. My
>search engine is so slow today.
>I would appreciate your help.
>Thanks everyone.
>Love, Hugs, Kisses,
>PJ
>143
>------------------------------------------------------------------------
>This is an automatically-generated notice. If you'd like to be removed
>from the mailing list, please visit the Medicine-On-Line Discussion Forum
>at <http://www.meds.com/con_faq.html>, or send an email message to:
>majordomo@lists.meds.com
>with the subject line blank and the body of the message containing the
line:
>unsubscribe mol-cancer your-email-address
>where the phrase your-email-address is replaced with your actual email
>address.
>------------------------------------------------------------------------
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
